Digital Transformation and Sustainability Evangelist Vijay Sethi Joins the Advisory Board of Cyble
11.5.2021 11:42:00 EEST | Business Wire | Press release
Cyble, an AI-powered, Y Combinator-backed, cyber intelligence company that empowers organizations with darkweb/cybercrime monitoring and mitigation services, today announced the addition of eminent technology and sustainability evangelist Vijay Sethi to its Advisory Board. Vijay has rich experience in advising and mentoring corporates and startups in various facets of management, digital transformation, and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005525/en/
Digital Transformation and Sustainability Evangelist Vijay Sethi Joins the Advisory Board of Cyble (Photo: Business Wire)
“A key member of our Advisory Board, Vijay’s insights will help steer our strategic development initiatives. His appointment is in line with Cyble’s commitment to achieving our goals by ensuring sustained growth, maintaining operational excellence, establishing a culture of innovation, and raising the standards for corporate governance. As Cyble continues to deliver advanced threat intelligence to its end-clients, I look forward to working with Vijay as Cyble continues to grow and span across uncharted territories,” says Manish Chachada, COO and Co-founder of Cyble.
An industry veteran with over 30 years of experience, Vijay Sethi has served as the CIO, CHRO, and Head CSR at Hero MotoCorp. Prior to that, he worked with Ranbaxy and Tata Consultancy Services. A huge proponent of digital technologies like the Cloud, Mobility, Artificial Intelligence, RPA, AR, VR, and cybersecurity and risk management, he has experience in digital transformation roadmap and project development ventures, large-scale IT projects, community development programs, and talent development and employee engagement campaigns.
Commenting on joining forces with Cyble, Vijay says, “I strongly endorse the growing need to make the digital world safer and help share cybersecurity insights and threat intelligence with consumers. The team at Cyble, their technological offerings, and the company’s commitment to keeping customers and users safe are impressive. I’m very pleased to be joining Cyble as an Advisor and look forward to working with its talented and dynamic teams.”
Rated among India’s Best IT leaders, over the years, Vijay has won several prestigious recognitions, including CIO of the year many times, CIO Hall of Fame, Super League CIO, Champion CIO, Global CIO, Global CIO Hall of fame, Digital Icon of India, India’s Best IT manager, India’s Most Innovative CSR Leader, and many others. He also serves as the Chairman of SAP India User Group (INDUS). Earlier, he also served as the Chairman of the IT Committee of Society of the Indian Automobile Manufacturers (SIAM) and the Chairman of CSR Committee of SIAM. Over the years, Vijay has also been a member of various Committees of CII and FICCI.
Beenu Arora, CEO and Founder of Cyble, says, “I am delighted to welcome Vijay into the board. He truly needs no introduction in the cybersecurity fraternity, and his problem-solving skills and passion for building efficient solutions make him best suited to take Cyble to the next level. His appointment has been a significant step in our effort to nurture our world-class business leadership team. Vijay’s actionable counsel will prove beneficial in shaping Cyble’s strategic business decisions.”
About Cyble:
Cyble is a global threat intelligence SaaS provider that helps enterprises protect themselves from cybercrimes and exposure in the Darkweb. Its prime focus is to provide organizations with real-time visibility to their digital risk footprint. Backed by Y Combinator as part of the 2021 winter cohort, Cyble has also been recognized by Forbes as one of the top 20 Best Cybersecurity Start-ups To Watch In 2020. Headquartered in Alpharetta, Georgia, and with offices in Australia, Singapore, and India, Cyble has a global presence. To learn more about Cyble, visit www.cyble.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005525/en/
Contact information
Medha Roy Chowdhury
EMAIL:
Enquiries@Cyble.io
MOBILE: +1 678 379 3241
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
